In October 2009, SME status was assigned to RESprotect by the European Medicines Agency (EMA). RESprotect has declared itself to be a micro-sized, autonomous enterprise within the meaning of Recommendation 2003/361/EC and is established in the Community. On the basis of this declaration, RESprotect is eligible to benefit from the provisions for administrative and financial assistance of the EMA.

About RP101: RESprotect is developing RP101 for the treatment of pancreatic and other cancers. RP101, given in combination with chemotherapy, is able to inhibit chemoresistance thereby maintaining sensitivity against chemotherapy. RP101 is the first small molecule known which specifically binds to heat shock protein 27 (Hsp27) and inhibits its effects in establishing cancer chemoresistance.

About RESprotect: RESprotect GmbH is a privately owned Biotech Company located in Dresden/Germany. RESprotect is focusing on the inhibition of chemoresistance and the enhancement of chemosensitivity of tumors. Chemogenomics, the approach of Resprotect, focuses on the application of small synthetic molecules, which elicit favourable phenotypic changes. The combination with genomic tools concentrating on specific biological pathways allows a better understanding of the broader effect of a drug. Thus, it is possible to discover drugs that target the cause of a disease rather than its symptoms. RESprotect's compounds are given additionally to standard chemotherapy. In contrast to the well known efforts to circumvent or decrease existing chemoresistance, RESprotect´s approach is unique.